Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

Sanofi’s pipeline remodeling program has claimed a pivotal combo approach to lung cancer along with a score of other terminations in Q4. And the moves underscore what’s hot — and not — in the oncology field.